Introduction
============

Postherpetic neuralgia (PHN) is a persistent neuropathic pain that remains after a herpes zoster rash has healed. It is the most common complication of herpes zoster infection. The incidence and treatment costs of PHN increase with age ([@B30]; [@B7]). Herpes zoster infection of the trigeminal nerve is a high risk factor for PHN ([@B24]). Trigeminal postherpetic neuralgia (TPHN) often presents with moderate to severe pain, hyperalgesia, and allodynia. Conventional analgesic treatments are ineffective, a consequence that greatly affects the quality of life and increases social burden ([@B10]; [@B19]). Finding a treatment that can effectively relieve TPHN and improve a patient's quality of life is imperative.

Trigeminal postherpetic neuralgia is a severe neuropathic pain that occurs when varicella-zoster virus infection affects the trigeminal gasserian ganglion or its divisions. Of the three divisions of the trigeminal nerve, the most commonly involved is the ophthalmic division (V1), which is 20 times more likely to be involved than the other two divisions, the maxillary (V2) division and the mandibular (V3) division ([@B14]; [@B22]). The incidence of ophthalmic herpes zoster is 19% of herpes zoster cases ([@B35]), just below the more common incidence of thoracic dermatome involvement ([@B23]). Drug treatment for the persistent pain is generally ineffective. Peripheral nerve block is a commonly used treatment that is effective, but there are limitations in its application, and the duration of pain relief is short. Pulsed radiofrequency (PRF) has been used for the treatment of chronic neurological pain. PRF treatment consists of short bursts of high energy current followed by a 480 ms heat dissipation interval, which assures that the temperature of the tissue being treated does not exceed 42°C. Thus, there is no damage to the nerve tissue ([@B4]), only modulation of nerve function ([@B16]). There is high incidence of V1 involvement in TPHN. V1 locates in an important anatomic area and great caution must be used in its treatment. The advantage of PRF is that it does not damage the nerve; therefore, there is no contraindication for using PRF for treatment of TPHN. Few studies have been conducted on PRF of the gasserian ganglion as treatment for TPHN.

In this study, PRF treatment of the gasserian ganglion was compared with PRF treatment of peripheral nerves (supraorbital, infraorbital, and mental nerves) for evaluation of its clinical efficacy and satisfaction in TPHN patients.

Patients and Methods
====================

Patients
--------

A total of 90 TPHN patients were selected between January 2014 and December 2016 in the Department of Pain Management, Shengjing Hospital, China Medical University ([Figure 1](#F1){ref-type="fig"}). The patients were randomly divided into two groups according to the order of enrollment (*n* = 45): group A, peripheral nerve PRF (supraorbital nerve, infraorbital nerve and mental nerve); group B, gasserian ganglion PRF. The distribution area of posterior herpes pigments or lesions were unilateral. After the PRF treatment, both groups received steroid injections. Patients were supplemented with anticonvulsants and opioid analgesics. Nutritional supplements that promote nerve recovery and other therapeutic drugs were the same in both groups. The study was approved by the Ethics Committee of Shengjing Hospital, China Medical University. All patients were informed of the risks and complications before surgery, and written informed consents were obtained.

![Study flowchart. All 90 patients were included in the treatment. PRF, pulsed radiofrequency.](fnins-13-00708-g001){#F1}

### Inclusion Criteria

\(1\) Average pain intensity score (visual analog scale, VAS) ≥5 points in 24 h before enrollment. (2) Skin lesions had healed, but there was still persistent, intense and intractable pain, local skin hyperalgesia, numbness, and sensory abnormalities. (3) Natural course more than 3 months and conservative treatment was ineffective. (4) Age \> 50 years old.

### Exclusion Criteria

\(1\) Epilepsy, trigeminal neuralgia, or intracranial space-occupying lesion. (2) Hematologic disease or abnormal coagulation, (3) Severe liver and kidney dysfunction or severe cardiopulmonary disease, (4) Drug abuse, (5) Mental illness/unable to cooperate with treatment.

Surgical Methods
----------------

The patient was placed in the supine position. Under CT guidance, the ipsilateral shoulder was positioned and attached to the electrode plate of the radiofrequency apparatus. In group A, PRF of peripheral nerves (supraorbital, infraorbital, and mental nerves) was performed. The point of supraorbital nerve puncture was located in the supraorbital orifice, immediately above the orbital ridge, using the medial line through the pupil as a reference for the supraorbital nerve; The point of infraorbital nerve puncture was located in the infraorbital foramen, can be approximated by having the patient look straight ahead and imagining a line down from the pupil to the inferior border of the infraorbital ridge, bicuspid teeth, and mental foramen; The point of mental nerve puncture was located in the mental foramen, located halfway between the upper (alveolar crest) and the lower edge of the mandible in direct line with the second bicuspid (premolar). In Group B, the Hartel anterior approach to access the gasserian ganglion was performed. The puncture point was positioned 2.5--3 cm from the corner of the mouth. After 0.5% lidocaine was used to anesthetize the ipsilateral-affected side of the mouth, the sterilized radiofrequency needle (21 G, length 100 mm and length of the active tip 5 mm) was guided along the established puncture angle until it reached the site of the foramen ovale. The needle was then guided to the gasserian ganglion. The radio frequency meter was tested to assure coverage of affected area: (1) 50 Hz, 0.1--0.3 V test sensation, to induce pain sensation in the herpes area. (2) 2 Hz, 0.1 V test exercise, jaw tremor will be induced when V3 division is affected. The radiofrequency stimulation tests determined whether the herpes area was covered. The position of the needle tip was adjusted until the movement and sensation determined that the affected area was completely covered and that normal areas were avoided. When the position was satisfactory, each point was treated with 42°C PRF for 300 s, and then 2 ml of an analgesic solution (2% lidocaine 1 ml + vitamin B12 0.5 mg + compound betamethasone 5 mg + normal saline 2 ml) was administered. ceftriaxone sodium was given 30 min before surgery to prevent infection. Vital signs were monitored during surgery. The patient's reaction was observed during the operation and adjustments made, if needed. The patients were restricted to absolute bed rest for 24 h post treatment.

Efficacy Evaluation and Follow-Up
---------------------------------

Presurgery data were recorded: gender, age, pain duration, presurgery VAS, pain location and divisions affected, and drug dosage of anticonvulsants and opioid analgesics. Follow-up assessments were performed at 1 week, 1 month, 3 months, 6 months, and 1 year after surgery. The non-surgical medical staff used a double-blind method to assess patients at follow-ups.

1.  Visual analogue scale: used to evaluate the degree of pain. No pain = 0 points; intense pain = 10 points.

2.  SF-36 evaluation ([@B15]): the quality of life was assessed before and after the operation, including physical and mental status. Physical states include physical function, role physical, bodily pain, and general health. Mental state includes vitality, social function, role emotional, and mental health. The physical component summary (PCS) and mental component summary (MCS) values were averaged.

3.  Total efficiency rate: according to subjective symptoms and clinical signs, the efficiency rate was divided into three grades: excellent, effective, and ineffective. Excellent -- pain, numbness and hyperalgesia disappeared, and labor levels returned to premorbid levels, effective -- pain and numbness were relieved, quality of life improved and ability to work increased, and ineffective -- no improvement in symptoms. The total efficiency rate was calculated as the number of patients scoring as "excellent" and "effective" divided by the total number of patients in the group.

4.  Drug dosage of anticonvulsants and opioid analgesics: anticonvulsants drugs included carbamazepine, gabapentin, and pregabalin; the opioid analgesic oxycontin was used.

Statistical Analysis
--------------------

The data were processed using SPSS18.0 analysis software. The measurement data was first tested for normality, and the single-sample Kolmogorov--Smirnov test was used in non-parametric tests. The normal distribution variables were expressed as mean ± standard deviation ($\overline{x}$ ± SD); One-way analysis of variance was used to compare, and then applied the LSD pairwise comparison. The variables that did not meet the normal distribution were expressed as the median ± interquartile range; The Kruskal--Wallis rank sum test was used in non-parametric tests. The enumeration data were analyzed by chi square test or Fisher's exact test. *P* \< 0.05 was statistically significant.

Results
=======

Needle Position on CT Scan and Three-Dimensional Reconstruction
---------------------------------------------------------------

All operations were completed successfully and no serious adverse reactions were observed. On the CT scan plane, the needle tips were located in the peripheral nerve (supraorbital nerve, infraorbital nerve, and mental nerve) or the foramen ovale, respectively. Three-dimensional CT (3D-CT) was performed to further clarify the path and position of the needle ([Figure 2](#F2){ref-type="fig"}).

![**(A-a)** CT scan and 3D-CT showed the path and position of the needle located in the right mental nerve, shown by the arrow; **(B-b)** CT scan and 3D-CT showed the path and position of the needle located in the right infraorbital nerve, shown by the arrow; **(C-c)** CT scan and 3D-CT showed the path and position of the needle located in the right supraorbital nerve, shown by the arrow; **(D-d)** CT scan and 3D-CT showed the path and position of the needle located in the right foramen ovale, shown by the arrow.](fnins-13-00708-g002){#F2}

Presurgery General Conditions
-----------------------------

Presurgery general conditions in the treatment groups included gender, age, pain duration, presurgery VAS, pain location and divisions affected, and presurgery drug dosages of anticonvulsants and opioid analgesics. No significant differences were observed in all general conditions before surgery (*P* \> 0.05) ([Table 1](#T1){ref-type="table"}).

###### 

Presurgery general conditions in patients.

  Parameters                                   Group                   
  -------------------------------------------- ----------------------- -----------------------
  Patients (*n*)                               45                      45
  Gender (M/F, %)                              20 (44.4)/25 (55.6)     22 (48.9)/23(51.1)
  Age (year, range)                            64.89 ± 8.96 (52--81)   64.76 ± 8.73 (53--82)
  Pain duration (m, range)                     6.26 ± 2.38 (3--9)      6.31 ± 2.46 (3--10)
  Presurgery VAS                               6.83 ± 1.41             6.76 ± 1.56
  **Pain location -- side of face (*n*, %)**                           
  Right                                        25 (55.6)               26 (57.8)
  Left                                         20 (44.4)               19 (42.2)
  **Divisions affected (*n*, %)**                                      
  V1                                           5 (11.1)                6 (13.3)
  V2                                           3 (6.7)                 3 (6.7)
  V3                                           13 (28.9)               14 (31.1)
  V1 V2                                        10 (22.2)               9 (20.0)
  V2 V3                                        11(24.4)                10 (22.2)
  V1 V2 V3                                     3 (6.7)                 3 (6.7)
  **Presurgery anticonvulsants drug dosage**                           
  Carbamazepine (mg/day, *n*)                  527.34 ± 73.51 (10)     528.62 ± 72.46 (11)
  Gabapentin (g/day, *n*)                      2.45 ± 0.35 (21)        2.53 ± 0.29 (19)
  Pregabalin (mg/day, *n*)                     434.68 ± 71.26 (14)     435.71 ± 72.42 (15)
  Presurgery opioids drug dosage                                       
  Oxycontin (mg/day, *n*)                      42.43 ± 12.67 (45)      43.08 ± 11.52 (45)
                                                                       

Visual Analogue Scale Pain Scores Presurgery and Postsurgery
------------------------------------------------------------

Visual analogue scale pain scores decreased in both treatment groups at each postsurgery time point (1 week, 1 month, 3 months, 6 months, and 1 year) and were significantly different from presurgery values (*P* \< 0.05). VAS decreased gradually in both groups, with the lowest values reached at 3 months, after which the VAS values increased slightly at 6 months and 1 year but still remained significantly lower than presurgery levels. VAS values in group B were significantly lower than group A at each time point (*P* \< 0.05) ([Figure 3](#F3){ref-type="fig"}).

![The comparison of VAS pain scores presurgery and postsurgery in both treatment groups. Results are presented as means ± SD. ^∗^Compared to presurgery, *P* \< 0.05; \#Compared with A group, *P* \< 0.05.](fnins-13-00708-g003){#F3}

SF-36 Quality of Life Evaluation Presurgery and Postsurgery
-----------------------------------------------------------

Both groups of patients had different degrees of improvement in quality of life, including physical function, role limitations due to physical health, bodily pain, general health, vitality, social function, role limitations due to emotional health, and mental health. The PCS and MCS increased in both treatment groups at each observation time point postsurgery (1 week, 1 month, 3 months, 6 months, and 1 year), and were significantly different from the preoperative values (*P* \< 0.05). PCS and MCS increased gradually in both groups. PCS and MCS values were the highest at 3 months, and decreased thereafter at 6 months and 1 year but still remained significantly higher than presurgery levels. Compared with group A, PCS and MCS increased significantly in group B (*P* \< 0.05) ([Figure 4](#F4){ref-type="fig"}).

![The comparison of quality of life scores (SF-36) presurgery and postsurgery in both treatment groups. PCS, physical component summary; MCS, mental component summary. Results are presented as means ± SD. ^∗^Compared to presurgery, *P* \< 0.05; \#Compared with group A, *P* \< 0.05.](fnins-13-00708-g004){#F4}

The Total Efficiency Rate Postsurgery
-------------------------------------

The total efficiency rates at 1 year after surgery in group A and group B were 68.9 and 86.7%, respectively. The total effective rate of group B was higher than that of group A, and the difference was statistically significant (*P* \< 0.05) ([Table 2](#T2){ref-type="table"}).

###### 

The comparison of total efficiency rate postsurgery in two groups (%).

  Group   *n*   Excellent   Effective   Ineffective   Total efficiency (%)
  ------- ----- ----------- ----------- ------------- ----------------------
  A       45    20          11          14            68.9
  B       45    27          12          6             86.7^∗^
                                                      

∗

Compared with A group,

P

\< 0.05.

Drug Dosage of Anticonvulsants and Opioid Analgesics Presurgery and Postsurgery
-------------------------------------------------------------------------------

The dosage of anticonvulsants (carbamazepine, gabapentin, and pregabalin) and opioid analgesic (oxycontin) used postsurgery decreased to varying degrees (or were even discontinued) in both treatment groups, and were significantly different from presurgery usage (*P* \< 0.05). The decrease in the dosage of anticonvulsants and opioid analgesic in group B was significantly different from the decrease observed in group A (*P* \< 0.05) ([Figure 5](#F5){ref-type="fig"}).

![The comparison of the dosage of antiepileptic and opioid drugs presurgery and postsurgery in both treatment groups. **(A)** Carbamazepine, **(B)** Gabapentin, **(C)** Pregabalin, and **(D)** Oxycontin. Results are presented as means ± SD, ^∗^Compared to presurgery, *P* \< 0.05; \#Compared with A group, *P* \< 0.05.](fnins-13-00708-g005){#F5}

Discussion
==========

Postherpetic neuralgia is a chronic neuropathic pain resulting from re-activation of the herpes zoster virus. The condition is persistent and unresolvable. Its etiology and mechanism are not fully known, and there are no completely effective therapeutic drug or treatment regimens. This study found that after PRF treatment, pain was relieved, quality of life was improved, and the dosage of anticonvulsants and opioid analgesics were reduced in both treatment groups (trigeminal peripheral nerve group and gasserian ganglion group). Gasserian ganglion PRF therapy was superior to peripheral nerve PRF in the relief of pain; the total efficiency rate and patient satisfaction was significantly higher.

The trigeminal nerve is the dominate sensory nerve of the face. After the initial infection of herpes zoster, the virus lies latent in the trigeminal gasserian ganglion. With a decrease in the body's immune system, the latent herpes zoster virus can reactivate and replicate. Peripheral nerves associated with the infected ganglion will exhibit lesions ([@B5]; [@B33]). Severe inflammatory reactions can occur in the invaded ganglia, manifesting as neuronal edema, necrosis, and internal hemorrhage of the nerve, which leads to neuropathic pain ([@B32]). Trigeminal herpes zoster with symptoms of severe pain has a high probability of developing into PHN ([@B21]). The pain from trigeminal herpes is different from PHN in other areas of the body ([@B31]; [@B27]); it is more difficult to treat and requires medical attention. Drugs and nerve blocks are the usual courses of treatment to relieve pain. However, incurable pain is often encountered clinically, and conservative treatment alone is ineffective.

Neurodestructive therapy is not recommended for PHN because of an increased chance for neurological damage and aggravation of neuropathic pain ([@B6]). PRF is a minimally invasive treatment of neuropathic pain ([@B29]). As opposed to conventional continuous radiofrequency (CRF) therapy, the temperature of the radiofrequency needle used in PRF does not exceed 42°C, so there is no nerve injury, only modulation of the nerve activity ([@B25]). PRF of peripheral nerves (supraorbital, infraorbital, and mental nerves) is commonly used ([@B17]). PRF treatment of the trigeminal gasserian ganglion, however, is able to target the core of the disease. The affected divisions of the trigeminal gasserian ganglion can be identified by RF current stimulation, allowing for treatment closer to the site of the disease and making the treatment more accurate.

The incidence of V1 division involvement is high. Due to the particular anatomy of V1, special care is required during treatment. Therefore, it is necessary to select a treatment method with less side effect. PRF has been shown to cause transient endoneural edema and collagen deposition without structural changes ([@B26]). The ultrastructural damage of axons, abnormal membrane, and mitochondrial morphology, microtubule and microfilament disintegration were observed under electron microscope ([@B8]), but all were reversible, and no contraindication for the treatment of TPHN were found. Therefore, TPHN was treated with gasserian ganglion PRF, and a CT-guided Hartel approach was used to puncture the foramen ovale for accurate positioning. Pain conduction was blocked and the vicious cycle of pain was interrupted temporarily. At the same time, the subsequent local injection of steroids had an anti-inflammation effect, eliminating edema, and improving blood circulation in the area of skin lesions. The functional recovery of damaged nerve terminals and skin receptors was promoted.

The analgesic mechanism of PRF is unclear ([@B18]). The PRF analgesic effect is not achieved solely through temperature ([@B26]), but through neuromodulation ([@B3]; [@B28]). The pain of PHN manifests as burning pain, intermittent sharp pain, paresthesia, thermal, and mechanical hyperalgesia ([@B9]). The various clinical manifestations of PHN suggest the involvement of the peripheral and central nervous systems, and pathophysiological mechanisms of multiple receptors, pathways, and neurotransmitters ([@B1]). It is currently believed that the effect of PRF might be at the microscopic or even subcellular level ([@B13]). PRF could selectively act on the fibrous structures of small myelinated Aδ and unmyelinated C pain afferent fibers axons ([@B12]), inhibit ectopic spontaneous discharge, and interfere with the conduction of nerve impulses. PRF has been shown to regulate the plasticity of synapses in neurons and transiently inhibit induced synaptic activity ([@B2]); the effect was reversible and less destructive than CRF treatment. It has also been suggested that the analgesic effect of PRF may be through enhancement of noradrenergic and serotonergic descending inhibitory pathways ([@B11]). PRF was found to regulate gene expression in a model of nerve injury; expression of GABAB-R1, Na/KATPase, and 5-HT3r anti-inflammatory cytokines were increased, whereas expression of TNF-α and IL-6 pro-inflammatory cytokines were decreased ([@B34]). In another study, the expression of endogenous opioid precursor mRNA (proenkephalin, pro-opiomelanocortin, and prodynorphin), and the corresponding opioid peptide were increased in cultured cells after PRF ([@B20]).

Our study showed that PRF effectively relieved the pain of TPHN in both peripheral nerve and gasserian ganglion treatment groups. The neuromodulation effect was relatively slow; the analgesic effect occurred gradually, becoming maximal at the 3 months follow-up. Although VAS increased slightly at the 6 months and 1 year time point, they stayed significantly lower than presurgery levels. The finding that pain was recurring in the latter time points may explain reports that PRF treatment needed to be repeated and combined with drugs and other therapies for optimal analgesia.

In summary, PRF is a recommend treatment to relieve the pain of TPHN. PRF treatment of gasserian ganglion was more effective than treatment of the associated peripheral nerves. The method was effective. PRF reduced VAS, significantly relieved PHN, increased the total efficiency rate, reduced the dosage of anticonvulsants and opioids analgesics, and improved the quality of life for the patients.
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